Anne Fagan Lab

Cerebrospinal fluid and plasma biomarkers of early-stage Alzheimer’s disease Read More

Research Overview

For the past ten years Anne has been investigating the mechanism(s) by which the E4 isoform of apolipoprotein E (apoE) is a risk factor for AD. Her multidisciplinary approach, utilizing biochemical and cell biological experiments coupled with analysis of in vivo transgenic mouse models of AD, has been instrumental in defining an important role for apoE in the metabolism of amyloid-b (Abeta), the protein that accumulates and forms plaques in the AD brain. Over the past five years, her interests have expanded into the AD biomarker field, with publications describing CSF lipoprotein-associated Abeta and sulfatide measures as candidate biomarkers of preclinical and early stage AD. Anne is a co-investigator on the biomarkers portion of a large, long-standing Program Project through the Washington University ADRC investigating brain and cognitive health during healthy aging and dementia. She is also the Principal Investigator of the biomarkers section of a newly funded Program Project (Adult Children Study) designed to identify antecedent biomarkers of AD (i.e., biomarkers to detect AD prior to clinical symptoms). In addition, Anne is supervising efforts to develop a relational database of existing antecedent biomarker studies and to coordinate development of common protocols for collection and analysis of biological samples and cognitive assessment.

Research Projects